FDA Adverse Event Injury Summary report: N

XIENCE PRO EVEROLIMUS ELUTING RX CORONARY STENT SYSTEM

MDR report key: 4200469 · Received October 24, 2014

Report

Report Number
2024168-2014-06981
Event Type
Injury
Date Received
October 24, 2014
Date of Event
September 27, 2014
Report Date
September 29, 2014
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P070015
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. INTIMAL DISSECTION IS LISTED IN THE XIENCE PRO EVEROLIMUS ELUTING CORONARY STENT SYSTEMS INSTRUCTIONS FOR USE (IFU) AS A KNOWN PATIENT EFFECT OF CORONARY STENTING PROCEDURES. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURING, DESIGN OR LABELING. THE ELECTRONIC LOT HISTORY RECORD (ELHR) WAS REVIEWED FOR THE REPORTED LOT AND THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY. THE XIENCE PRO IS CURRENTLY NOT COMMERCIALLY AVAILABLE IN THE US. THE PRODUCT CODE LISTED AND THE PMA# LISTED IS BASED ON THE PREDICATE DEVICE (XIENCE V) AND IS THEREFORE SIMILAR TO A DEVICE SOLD IN THE US.

Description of Event or Problem · 1

IT WAS REPORTED THAT DURING A HEAVILY CALCIFIED, HEAVILY TORTUOUS, MID CIRCUMFLEX CORONARY ARTERY PROCEDURE, DURING USE OF THE 2.5 X 28 MM XIENCE PRO A DISSECTION OCCURRED. ANOTHER NON-SPECIFIED STENT WAS USED TO COVER THE DISSECTION. THERE WAS NO ADVERSE PATIENT SEQUELA AND NO CLINICALLY SIGNIFICANT DELAY IN THE PROCEDURE. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
678767 XIENCE PRO EVEROLIMUS ELUTING RX CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 3080941

Patients

Seq Age Sex Outcome Treatment
1 64 YR Required Intervention